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ABSTRACT: Oligonucleotides (ONs) comprise a rapidly growing class
of therapeutics. In recent years, the list of FDA-approved ON therapies
has rapidly expanded. ONs are small (15−30 bp) nucleotide-based
therapeutics which are capable of targeting DNA and RNA as well as
other biomolecules. ONs can be subdivided into several classes based on
their chemical modifications and on the mechanisms of their target
interactions. Historically, the largest hindrance to the widespread usage
of ON therapeutics has been their inability to effectively internalize into
cells and escape from endosomes to reach their molecular targets in the
cytosol or nucleus. While cell uptake has been improved, “endosomal
escape” remains a significant problem. There are a range of approaches
to overcome this, and in this review, we focus on three: altering the
chemical structure of the ONs, formulating synthetic, lipid-based
nanoparticles to encapsulate the ONs, or biologically loading the ONs
into extracellular vesicles. This review provides a background to the design and mode of action of existing FDA-approved ONs.
It presents the most common ON classifications and chemical modifications from a fundamental scientific perspective and
provides a roadmap of the cellular uptake pathways by which ONs are trafficked. Finally, this review delves into each of the
above-mentioned approaches to ON delivery, highlighting the scientific principles behind each and covering recent advances.
KEYWORDS: oligonucleotide, oligonucleotide delivery, intracellular trafficking, endosomal escape, RNA therapeutics, lipid nanoparticles,
extracellular vesicles, cellular uptake
RNA THERAPEUTICS OVERVIEW
The field of nucleic-acid-based therapeutics is entering an era
highlighted by increased clinical success and intense interest by
pharmaceutical and biotech industries. The continuous
improvements in nucleic-acid-based drug compositions along
with the extensive mapping of genetic targets are fueling the
exponential growth of applications for these therapies.
The Food and Drug Administration (FDA) broadly defines
gene therapy as therapy that seeks to modify or manipulate the
expression of a gene or to alter the biological properties of
living cells for therapeutic use.1 This is often accomplished by
delivering exogenous nucleic acid sequences to the cells of
interest. These sequences may include DNA, RNA, a range of
synthetic analogues which are based off of these two natural
nucleic acids, or quite often a mix thereof. In addition,
functional delivery is often boosted by addition of other
bioactive compounds and macromolecules such as lipids and
peptides. The ability to construct these complex molecules has
resulted in a wave of medical innovation. Using the approaches
outlined in this review, nucleic-acid-based therapies can be
used to treat a range of diseases which have remained
unreachable through classical pharmacological intervention.
Recently, the outbreak of the SARS-CoV-2 virus has
prompted a significant shift of focus into the RNA therapeutics
space as Moderna Therapeutics and Pfizer/BioNTech
developed mRNA vaccines to combat the ongoing pandemic.
As much of the media focus highlighted the novelty of using
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RNA in a vaccine, it could be overlooked that an equally
important feat was the development of the lipid nanoparticle
(LNP) formulations that enabled cellular administration and
hence therapeutic functionality of the mRNA. The develop-
ment of these vaccines was also dependent on the ability to
mass-produce RNA therapeutics. Broadly, RNA therapeutics
can be classified as either mRNA-based or small RNA-based.
Both classes are growing rapidly in scientific and therapeutic
interest.
Oligonucleotides (ONs) are small nucleic acid strands which
are typically 15−30 base pairs in length and contain various
chemical modifications to favorably alter their behavior. These
short sequences can bind with exceptional specificity and
affinity to almost any RNA sequence, whether in pre-mRNA,
mRNA, ribonuclearproteins, or miRNAs. ONs can furthermore
be designed to assemble to a specific 3D conformation capable
of binding proteins. The inherent combinatorial nature of
nucleic acid sequences provides an immediate advantage in
terms of drug design; any nucleic acid target can be addressed,
while the pharmacokinetic properties of the drug can be tuned
separately. The pharmacokinetics of an ON are generally
determined by the backbone chemistry, while the target is
determined by the nucleotide sequence. In contrast, small-
molecule compounds are often extremely limited in their
ability to separate these two characteristics.2
Still, significant hurdles remain for widespread use of ONs
and other nucleic-acid-based therapeutics, which must be
overcome at almost all levels from drug design to functional
delivery:
• Chemical: the therapeutic molecules must have an
adequate half-life and stability.
• Cellular: the molecules must be able to enter cells in
adequate concentrations and usually cross biological
lipid membranes to reach their sites of action. Addi-
tionally, the ONs should be able to effectively target
specific cells and evade others.
Table 1. Current FDA-Approved ON Therapeuticsa
drug name developer FDA approval indication target class, Merb chemical modifications
Vomivirsen
(Vitravene)
Ionis Pharm. and Novartis
Opthalmics
Aug 26, 1998 CMV
retinitis




NeXstar Dec 14, 2004 retinal
AMD
VEGF-165 aptamer, 27 •PS 3′-3′ deoxythymidine cap
•2′-OMe purine ribose sugars













Jazz Pharmaceuticals Apr 1, 2016 sVOD nonspecificc mixed (avg. 50) •PO backbone
•single and double stranded
Spinraza
(Nusinersen)
Ionis Pharm. Dec 23, 2016 SMA SMN1 and SMN2
pre-mRNA












Ionis Pharm. and Akcea
Therapeutics
Oct 5, 2018 hATTR TTR mRNA gapmer, 20 •2′-O-MOE
Givlaari
(Givosiran)




























Sarepta Therapeutics Feb 25, 2021 DMD dystrophin pre-
mRNA
SSO, 22 •PMO
aAbbreviations: CMV, cytomegalovirus; PS, phosphorothioate; AMD, age-related macular degeneration; 2′-OMe, 2′-O-methyl; 2′-F, 2′-fluoro;
PEG, polyethylene glycol; HoFH, homozygous familial hypercholesterolemia; 2′-O-Moe, 2′-O-methoxyehtyl; DMD, Duchenne muscular
dystrophy; PMO, phosphorodiamidate morpholino oligomer; sVOD, severe hepatic veno-occlussive disease; PO, phosphodiester; SMA, spinal
muscular atrophy; hATTR, hereditary transythyretin amyloidosis; LNP, lipid nanoparticle; AHP, acute hepatic porphyria; GalNAc, N-
acetylgalactosamine; PH1, primary oxaluria type 1; FGF2, fibroblast growth factor 2. bEuropean Medicines Agency refused marketing authorization
on Dec 13, 2012. cIt is hypothesized that the DNA oligomers mimic heparin, binding proteins, primarily FGF2.
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• Immunological: the molecules should stimulate appro-
priate immunorecognition outcomes but should not
induce an undesired immune response.
• Tissue: the targeted cells must have been corrected in a
high enough quantity and in a time-dependent manner
to overcome the tissue’s weakness or defect.
• Clinical (patient-facing): the specificity of the drug to
the desired tissues must be high and toxicity must be
low, and off target affects must be minimal.
• Clinically (population-facing): the drug must be readily
scalable and affordably produced to be a practical
therapeutic, with a predictable behavior across the
population.
These barriers have been known to researchers for years;
however, there are still improvements which need to be made.
In particular, the infamous “endosomal escape” problem has
proven difficult to solve. This involves the inability of
biomolecules such as ONs to permeate endosomal membranes
and gain access to the cytosol. Three promising approaches to
overcome this barrier have emerged: chemically altering naked
ONs to give them favorable properties, formulating synthetic
lipid-based nanoparticles capable of inducing endosomal
release, and loading ONs into biological vesicles to exploit
natural delivery pathways. The aim of this review is to
summarize the recent clinical advancements of ON therapeu-
tics and to discuss in-depth the underlying scientific develop-
ments regarding the chemistry and uptake of ONs, specifically
through three delivery strategies: administering chemically
modified ONs, formulating lipid nanoparticles to deliver ONs,
and designing extracellular vesicles to deliver ONs.
Commercial Advancements in ON Therapeutics.
Although ONs were shown to target RNA and inhibit protein
translation in 1978,3 it took 20 years before patients received a
commercial ON treatment. ONs do not fall within the scope of
advanced therapy medicinal product (ATMP) regulations as
they are classified as chemical drugs by the FDA and the
European medicines agency (EMA).4 Ionis Pharmaceuticals
(formerly Isis Pharmaceuticals) earned FDA approval for an
ON drug in 1998 with the development of Vitravene
(fomivirsen), which was used for the treatment of
cytomegalovirus (CMV) retinitis in AIDS patients.5 The
problem of tissue targeting was overcome by administering the
drug via intraocular injection. However, the commercialization
of this ON was not entirely successful. Fomiversen’s market
share has fallen considerably due to the introduction of a small-
molecule drug for the same condition. Additionally, the next
two ONs to receive FDA approval, Macugen (pegaptanib) and
Kynamro (mipomersen), experienced difficulties after they
made it to market.6 Both ONs failed to maintain strong market
share due to competing antibody-based and small-molecule
therapeutics. However, 2016 marked a turning point in two
significant FDA approvals: Exondys 51 (Eteplirsen) for
Duchenne muscular dystrophy (DMD)7 and Spinraza
(nusinersen) for spinal muscular atrophy (SMA), discussed
further below.8 The complete list of FDA-approved ON
therapies as of today is shown in Table 1.
Figure 1. Commonly used types of ONs and their target species. Five types of ONs are discussed in this review. Gapmers target mRNA with
high affinity thanks to LNA base pairs. The unmodified nucleotides in the central region allow RNase H1 to bind, degrading the mRNA.
Splice-switching ONs target splice sites of pre-mRNA, preventing the splicing machinery from forming and altering the resultant mRNA.
Aptamers have a 3D structure which mimics the ligands of the proteins they target with high specificity and affinity. The guide strand of
double-stranded siRNA guides the RISC to the target mRNA, leading to RISC-mediated degradation. miRNA is activated by cleavage by
Dicer, where it binds to mRNA preventing the formation of RNP complexes and ultimately destabilizing the mRNA. Abbreviations: SSO,
splice switching ON; siRNA, short inhibiting RNA; RISC, RNA-induced-silencing complex; miRNA, micro-RNA; mRNP, mRNA−protein
complex. Figure created in BioRender.
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ONs which have not met their clinical trial end points also
continue to provide valuable insights into the development of
future drugs. For example, in 2016, Alnylam Pharmaceuticals
had two ON therapies (siRNA-based) in phase III trials for
human transthyretin amyloidosis (hATTR), patisiran and
revusiran. While both drugs utilized delivery strategies to
target the liver, they differed in their delivery approach
revusiran was administered subcutaneously and was composed
of siRNA conjugated to the carbohydrate N-acetylgalactos-
amine (GalNAc); patisiran was an siRNA formulated within a
lipid nanoparticle (LNP). Revusiran, although capable of
efficient delivery, never gained FDA approval due to a high
mortality rate in a phase III study.9 Although the
discontinuation of revusiran was a major setback to Alnylam
and the ON field, the GalNAc conjugation delivery approach
later reached clinical relevance when Alnylam received
approval for givosiran in 2019. Givosiran targets the liver for
the treatment of acute hepatic porphyria (AHP).
Since fomiversen received approval in 1998, the field of
antisense technology has matured significantly, with some
products advancing to approval quickly while others are
hindered due to a number of scientific and regulatory factors.10
Additionally, disease targets have been mapped across a range
of diseases, providing numerous opportunities for intervention
with ONs. At the beginning of 2021, there were over 200
clinical trials registered for ONs in the oncology space in the
USA.11 Further, current clinical trials are using ONs to treat
cardiovascular diseases, metabolic diseases, and, among others,
infectious diseases such as hepatitis.12 In order to understand
where the next medical and scientific advancements lie, the
underlying science of the field must be considered.
CLASSES OF ON THERAPEUTICS
ONs have been developed to target DNA, RNA, protein
regions, and even post-translational modifications. Here, the
most clinically relevant classes of ONs are summarized along
with examples of FDA-approved ON therapies. A general
illustration of the classes discussed herein is found in Figure 1.
Several other types of ONs have been identified and
synthesized. A recent review by Smith and Zain comprehen-
sively reports the broad range of ON therapeutic strategies in
more depth.13 Additionally, other classes may emerge as we
expand our understanding of the many regulatory roles of
RNA.
Gapmers. Gapmers have historically been the most widely
used class of antisense ON (AON) therapeutics.13 The
sequence of a gapmer is fully complementary to its target
RNA strand so that binding occurs via Watson−Crick base
pairing. The gapmer contains a middle region of 6−10 DNA
nucleotides, which is flanked on either end by 3 to 5 modified
oligonucleotides. These modified nucleotides should contain
chemical modifications (discussed below) that increase both
nuclease resistance and target binding affinity.13 The name
“Gapmer” was coined for this DNA “gap” between the
modified nucleotides. Gapmers operate by binding their target
mRNA sequence and sequentially recruiting RNase H1, an
endogenous RNase which cleaves the RNA strand of a DNA−
RNA duplex in both the cytoplasm and the nucleus.14
Gapmers have received particular attention for their ability
to successfully silence genes in cells which are traditionally
difficult to transfect, such as T-cells.15 They have shown
promise in vivo for their gene-silencing potency, even showing
a higher potency than siRNAs in certain cases.16 Inotersen is
an approved gapmer therapeutic which targets transthyretin
(TTR) mRNA to reduce pathogenic TTR aggregation in
individuals with hereditary transthyretin amyloidosis. In a
phase I clinical trial, a 22 day schedule of subcutaneous
administration of 300 mg of inotersen led to reductions of
plasma TTR protein up to 76% for 4 weeks after the last
dose,17 and the drug is now used in the treatment of the
polyneuropathy of hereditary transthyretin-mediated amyloi-
dosis in adults.
Splice-Switching ONs (SSOs). SSOs are a class of steric
block ONs that emerged in the early 1990s.18 While gapmers
lead to degradation of the mRNA, SSOs redirect splicing
without depleting mRNA transcript levels, which is particularly
valuable in cases of disease where abnormal splicing depletes
functional protein. SSOs work by masking a splice site or
silencing and enhancing elements in exons and introns, leading
to the failure of the spliceosome to assemble and/or read
properly. Pre-mRNAs with weak splice sites are generally
better suited for targeting with SSOs than with gapmers as they
are already prone to produce various protein isoforms. SSOs
can work to either restore function in dysfunctional splice
variants or to impede the splicing of pathological variants
including viral transcipts.19,20
SSO structure differs from gapmer structure, as SSOs should
be designed to prevent RNase recruitment as their purpose is
not to induce mRNA degradation. SSOs are designed to utilize
chemical modifications which increase their stability, cellular
delivery, and binding affinity. These include for example
morpholinos, 2′-OMe phosphorothioate, LNAs, and other
modified nucleotides.21,22 As inferred by Table 1, SSOs have
proved particularly useful for treatment of SMA and DMD. In
2009, morpholino SSOs were able to achieve a dose-dependent
restoration of functional dystrophin without any adverse events
reported.22 Since 2016, half of the FDA-approved ON
therapeutics have been SSOs. Eteplirsen is a morpholino
SSO which targets exon 51 of dystrophin pre-mRNA, leading
to exon-skipping in the DMD gene which yields a truncated
yet functional dystrophin protein. The phase II study of
eteplirsen revealed that it was tolerated very well when treated
up to 20 mg/kg for 12 weeks.23 However, the results of this
study and yet another phase II trial have only been able to
induce modest increases of dystrophin expression. Further-
more, the methods used in these clinical trials were heavily
disputed, leading to a delay in market approval.24,25 Ultimately,
the FDA approved eteplirsen in 2016. Another SSO with a
significant history is nusinersen, a modified SSO which targets
survival motor neuron 1 and 2 (SMN1 and SMN2,
respectively) pre-mRNA in patients with SMA. The severity
of SMA is dependent primarily on the absence of SMN1 and
the absence of SMN2 to a lesser extent. The more functional
transcripts of these genes a patient has, the less severe the
disease outcome will be. Nusinersen works by masking a
weakened splice site to restore inclusion of exon 7 into SMN2,
enhancing production of the full-length protein variant.
Importantly, as only a small fraction of ONs can cross the
blood−brain barrier, nusinersen must be administered intra-
thecally by lumbar puncture. In two separate phase III studies,
nusinersen was found to drastically improve motor function in
young children.26,27 Both trials were ended early due to
favorable outcomes in the drug-treated subjects. Additionally, a
phase II trial in which nusinersen was given to presymptomatic
children found that most children (>88%) achieved normal
motor function development.28
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Aptamers. Aptamers are synthetic structural binding
elements composed of nucleic acids.13 They are single stranded
with a function reliant on their folded 3D structure. Aptamers
are produced in vitro through a process called systematic
evolution of ligands by exponential enrichment (SELEX), a
method of ligand screening for specificity.29,30 Aptamers have
been nicknamed “chemical antibodies” due to their ability to
recognize and bind proteins in a similar fashion to protein
antibodies.31 It was previously believed that aptamers were
immunoinert; however, it has since been demonstrated that
single-stranded DNA ONs have the potential to activate
immune responses when administered in blood.32 The
advantages of aptamers over antibodies are numerous:
aptamers exhibit better uptake due to their relative smaller
molecular weight compared to proteins and they can be
chemically synthesized at scale, whereas protein antibody
production is a far more laborious process.33 Additionally,
aptamers can be rapidly “turned off” with administration of a
complementary ON strand.34,35 Despite these numerous
advantages, aptamers are not yet a competitive therapeutic
alternative to protein antibodies as the only FDA-approved
aptamer, pegaptanib, is losing market share to a more
efficacious monoclonal antibody.36
Micro-RNA (miRNA). miRNAs are naturally present
double-stranded RNA ONs, usually found within intronic
regions of RNA. They undergo a two-step RNase III-
dependent processing to create primary miRNA (pri-
miRNA) hairpin structures which are cleaved into an active
form by Dicer, an endoribonuclease enzyme.37 The Dicer
cleavage forms a 21 nucleotide, double-stranded miRNA.
miRNAs work through the RNA interference mechanism,
which is the main post-transcriptional gene-silencing mecha-
nism. This includes the miRNA binding in the 3′ untranslated
region of mRNA, leading to loss of the poly-A tail and
consequent mRNA destabilization.38 As a result, the mRNA is
prevented from forming mRNA−protein structures (mRNPs)
and therefore protein translation from the mRNA cannot be
initiated.39 Additionally, it is believed that miRNAs can switch
roles between translation repression and activation according
to cell cycle phase.40
Several hundreds of endogenous miRNAs have been
identified and extensively characterized. They have been
investigated and mapped as biomarkers in a diagnostic
approach toward cancer detection.41 miRNAs found in
circulation may also be present as a result of their role in
immune system communication. miRNAs have both physio-
logical and pathological roles in the immune system.42−44
There exists an opportunity to further characterize the
connection between miRNAs and the immune system,
demonstrated by the fact that several clinical trials are being
conducted for therapeutics which target miRNAs have led to
immunological adverse effects.45
Therapeutic strategies involving miRNAs fall into two
categories: antimiRs and miRNA mimics. AntimiRs, as their
name suggests, are antagonists to miRNAs and function by
binding and deactivating endogenous miRNAs.46 miRNA
mimics, on the other hand, are exogenous and act to boost
the activity of the endogenous miRNAs. Both antagomirs and
mimics can be synthetically modified to increase their stability
and binding affinity.
Short Interfering RNA (siRNA). siRNAs are usually 20−
25 base pairs long and delivered to the cell as a double-
stranded RNA duplex, which includes a guide strand and a
passenger strand. The guide strand is designed to be
completely complementary to their target sequence. Once in
the cytosol, the guide strand dissociates from the passenger
strand and binds to endogenous Ago2, the key nuclease
component of the RNA-induced-silencing complex (RISC).
The guide strand then directs this protein complex to the
target mRNA.47 While gapmers bind their target sequence and
then recruit the nuclease, siRNA binds the nuclease complex
(RISC) and then targets the mRNA. Due to their intrinsic
ability to specifically silence gene expression by degrading
mRNA, siRNAs have most commonly been utilized to
downregulate protein expression levels.
Ago2 and the RISC complex have specific structural
requirements that the ONs must contain in order to bind.
This limits the extent of chemical modification that the siRNA
can undergo and in turn its stability and cellular uptake. So far,
three siRNAs which contain partially modified bases have
shown clinical success and attained FDA approval, beginning
with patisiran.48 Patisiran is a modified siRNA which is
formulated with a lipid nanoparticle (LNP) carrier to target
TTR mRNA. Administration of 0.3 mg/kg patisiran every 3
weeks for 18 months was able to decrease TTR levels up to
87.8%.49
CHEMICAL MODIFICATIONS OF RNA ONs
Unmodified DNA and RNA exhibits minimal therapeutic
activity because they are rapidly degraded, exhibit poor cellular
uptake and/or are filtered out of blood in biological
environments. In order to overcome these problems, enormous
efforts have been made to identify ON chemistries, naturally
occurring and synthetic, which improve the target binding
affinity, plasma stability, resistance to degradation, and
pharmacokinetics. Most of the currently utilized chemistries
for ONs have been resolved and characterized for several years
and the fact that they are still widely used implies that they
have proven to be highly effective.50 The structure of an ON
can be modified at all three of the functional regionsthe
nucleobase, the carbohydrate, and the phosphodiester linkage.
Nucleobase Modifications. Base modifications are often
used when stronger Watson−Crick base pairing is needed. By
modifying the base of the nucleotide, a higher affinity for the
target nucleotide can be achieved. This increases the thermal
stability of the duplex formed between the ON and its target
RNA, which can greatly increase the activity when using ONs
for mRNA-silencing. If the ON has bound its target RNA
tightly enough, splice sites can be hidden, ribosomal assembly
can be prevented, and translation can be inhibited.51
Additionally, base modifications can act to strengthen the 3D
structure of aptamers.52 It must be noted, however, that the
increased binding affinity may increase the risk of off-target
binding and thus the risk of adverse effects.
The 5-position of pyrimidines is a commonly utilized
location for modification.53 The most commonly utilized is the
“5-methyl-C” chemistry in which a methyl group is attached.
The increase in stability is attributed to the stacking of the
methyl groups between the nucleobases in the major groove of
the formed RNA duplex. Importantly, the modification seems
to act unfavorably if it is too large, as another common 5-
position modification, the 5-propynyl group, has been shown
to impede siRNA-mediated silencing due to the fact that it is a
relatively bulky modification and the RISC cannot properly
attach.54
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There exist further synthetic base modifications including
tricyclo DNA (tcDNA) and others, covered more in depth in a
recent review by Smith and Zain.13
Carbohydrate Modifications. The deoxyribose in DNA
and the ribose in RNA can be modified to increase the oligo’s
stability against nuclease degradation, greatly enhancing its
pharmacokinetic half-life from a matter of days to weeks.55
This is due to the fact that an electron-withdrawing group on
the 2′ carbon of ribose can induce the ribose to pucker into a
conformation which is favorable for duplex formation.13 This is
the reason RNA−RNA duplexes are more stable than DNA−
DNA duplexes, and several ON chemistries aim to replicate
this structure. Hybridization analysis of several 2′-modifica-
tions revealed that not all modifications enhance RNA affinity
equally.56 The most widely utilized modification is the 2′-O-
methyl (2′-O-Me) in which a methyl group is attached. Other
common modifications include 2′-O-methoxyethyl (2′-O-
MOE), and 2′-fluoro RNA (2′-F-RNA).
The carbohydrate can also contain modifications in which
“lock” the nucleotide into its north conformation. By bridging
the 2′-O to the C4′ with a methylene linkage, a drastic increase
in duplex stabilization can be achieved. This chemistry, the
locked nucleic acid (LNA), has since been effectively used in
siRNAs, gapmers, splice-switching ONs, and antagomirs.57
Phosphodiester Linkage Modifications. The backbone
of a nucleic acid strand is the repetitive sequence between
sugar group and phosphodiester linkage which effectively gives
the strand its helix shape. The backbone is also the target for
degradative endo- and exonucleases. The nonmodified
phosphodiester (PO) linkage of human DNA and RNA has
several unfavorable pharmacokinetic and distribution proper-
ties for its use as a therapeutic, including a short half-life in
circulation due to nuclease susceptibility and low serum
protein binding ability.
The most commonly employed chemical modification in
both research and clinical use is the phosphorothioate (PS)
modification. In the PS backbone, a nonbridging oxygen of the
phosphodiester linkage is replaced with a sulfur atom. The
foremost advantage to this substitution is that the PS-ON gains
resistance against nuclease degradation.58 As the chemistry was
studied further, it was also found that the PS backbone was
inducing an increase in tissue uptake.59 When PO-ONs are
administered by injection in vivo, they are rapidly degraded
into their constituent monomers and cleared in urine without
any significant delivery to tissue.60 However, PS-modified ONs
show much better tissue uptake with as little as 10% of the
administered dose cleared in urine, and even the cleared ON
had not been degraded.61 It is believed that PS-ONs are
retained in circulation due to their increased binding affinity
for serum proteins such as albumin, which helps them to evade
blood clearance long enough to reach their target tissues. PS-
ONs accumulate most readily into kidney and liver, with the
kidney having 84:1 organ-to-blood ratio and the liver having
20:1 at 2 h after injection.60
Interestingly, it was later found that the PS backbone exists
in nature in certain bacteria DNA.62 In nature, some bacteria
contain CpG motifs, C-G dinucleotides which are partially
modified to contain PS backbone linkages. CpG dinucleotides
have been found to bind TLR9, triggering immune stimulation
and B-cell activation.63 This finding has been the basis for
many therapeutic developments in which CpG-containing
ONs are used as immunostimulatory therapeutics against
allergies, cancer, and a range of other immunological
disorders.64
Importantly, the activity of PS-ONs cannot always be
correlated between in vivo and in vitro experiments due to the
delicate dependency on time, temperature, concentration, and
cell line used.65 The most common problems with using a PS
linkage include the decrease in binding affinity to the target
RNA/DNA and nonspecific protein binding. To compensate
for this, the PS chemistry is often used together with base and/
or sugar modifications which increase target binding affinity.
Phosphorothioamidate morpholino oligomer (PMO) ONs
contain a modified backbone in which the phosphodiester
linkage and the ribose sugar ring are replaced with synthetic,
noncharged morpholine linkages. The advantages to such a
Figure 2. Common chemical modifications for RNA ONs. The three sites for common modifications of RNA ONs include the nucleobase,
the phosphate backbone, and the carbohydrate sugar. Advantageous characteristics of modifications are listed for each site, and chemical
modifications which are utilized FDA-approved ONs are listed for each. The 5-carbon of the nucleobase and the 2′-carbon of the
carbohydrate are annotated with their relevant location number. Abbreviations: PS, phosphorothioate; PMO, phosphorodiamidate
morpholino oligomer; 2′-OMe, 2′-O-methyl; 2′-O-MOE, 2′-O-methoxyethyl; 2′-F, 2′-fluoro; LNA, locked nucleic acid. Figure created in
BioRender.
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chemistry can include high efficacy and specificity, nuclease
resistance, aqueous solubility, and low production costs.66
However, the incorporation of the PMO chemistry lowers the
ON melting temperature, which may be compensated for by
increasing the number of bases in the sequence. However,
PMOs also have a decreased binding affinity for serum
proteins, which leads to rapid blood clearance and limited
tissue distribution. The two PMO ONs which have received
FDA approval, eteplirsen and golodirsen, suffer from high
clearance with 66 and 60%, respectively, of intravenous (IV)-
administered ON being recovered in urine within 24 h of
administration.67,68
BIOCONJUGATION
Apart from modifying the internal chemical structures on the
ON, the possibility exists to chemically modify an ON by
conjugating other molecules to it. This can serve the purpose
of influencing the targeting and uptake of the ONs on the
tissue and cellular level. Additionally, bioconjugates have been
shown to alter the kinetics of the therapeutic ONs. Recent
work from Alnylam Pharmaceuticals has shown that N-
acetylgalactosamine (GalNAc), when conjugated to therapeu-
tic ONs, do not actively induce endosomal escape of the ON
but rather serve to increase the uptake and storage of the ON
within cellular compartments, leading to a sustained
therapeutic outcome in vivo.69 Through this approach, a single
administration of GalNAc-conjugated siRNA can lead to
silencing of the target gene that persists for weeks.
Some of the most commonly utilized bioconjugates include
cholesterol and N-GalNAc, but bioconjugates can also include
other lipids, sugars, antibodies, and peptides. Cell-penetrating
peptides (CPPs) have been used as a bioconjugate, which
bolsters the activity of the covalently lined ON. While CPPs
have proven effective to increase ON activity in vitro, their
mechanism of action is not entirely elucidated. It has been
shown that CPPs can be designed to work either by pore
formation in the plasma membrane or by endosomal
destabilization, although the latter is not well-defined.70,71
As bioconjugates do not necessarily induce endosomal
escape but may rather increase ON activity by other means,
bioconjugates lie outside the scope of this review. However, a
recent review from Kulkarni et al. thoroughly covers the use of
this effective delivery strategy in more depth.72
UPTAKE OF NAKED ONs (GYMNOSIS)
Although the hydrophobicity of the cell membrane prevents
ONs from permeating freely through, it was shown in 2009
that appropriate dosing can trigger cells to internalize naked
LNA ONs in a process known as gymnosis.73,74 Therefore, at
least one endocytic route for naked ONs must exist. The exact
mechanisms driving ON endocytosis are not completely
understood. Due to this, ON uptake has been broadly
classified as “productive” (yielding a functional outcome in
the recipient cells) or “unproductive”.
The uptake process can be divided into three stages:
association, internalization, and trafficking, discussed in-depth
below. Whether modified ONs are being delivered via
gymnosis or shuttled into the cell by delivery vehicles, they
must escape the endosomal compartment to reach their targets
in the cytosol or nucleus. This has proven to be the limiting
step in ON delivery, known as “endosomal entrapment”. A
considerable portion of recent research has focused on
manipulating the association, internalization, and trafficking
processes to encourage endosomal compartments to release
their cargo. This release, referred to as “endosomal escape”, has
become the predominant focus area in the development of
RNA therapies.
Additionally, a major factor in determining the therapeutic
outcome of an ON lies in its ability to induce the proper
immunostimulatory response. Depending on the therapeutic
mechanism of the ON, this can include immune evasion or
intentional immune recognition and activation. For antisense
ONs, it is usually the case that immune avoidance is desired so
the ON can reach its target cell without inducing toxicity and
other off-target gene effects associated with the inflammatory
response.75 For example, unmodified ONs can activate the
innate immunity by binding pattern-recognition receptors
(PRRs) such as Rig-I and PKR, which detect double-stranded
RNA in the cytoplasm.76,77 In this case, it is desired to design
antisense ONs to evade immune recognition. It has been
shown that certain chemical modifications such as 2′-OMe-
modified uridine and guanidine residues, discussed above, can
be incorporated to achieve immune evasion in siRNAs.78
Unfortunately, the means by which ONs can induce immune
activation are not completely elucidated, and it is not
uncommon for ONs which were promising in vitro to fall
short of their end points in vivo due to their immunogenicity. It
should be noted that ONs with neutral backbones have not
been implicated in immune activation.79,80 Conversely,
unmethylated CpG-containing ONs activate another PRR,
Toll-like receptor 9 (TLR-9), which stimulates the innate
immune system. CpG-containing ONs have therefore been
tested clinically as vaccine adjuvants and for cancer
immunotherapy.80−82
Association. The first stage of uptake, association, occurs
as the ON makes contact with proteins on the cell’s surface.
PO-ONs show a very low potential for binding to the cell
surface. The PS backbone modification has been found to
increase binding affinity of naked ONs to proteins on the cell
surface. In 1997, it was found that scavenger receptors on
endothelial cells were able to bind certain ON species.83 More
recently, class A scavenger receptors (SCARAs) have been
implicated as the principle association target of peptide-
conjugated PMOs, tcDNA, and ONs containing 2′-OMe
modifications.84 Serendipitously, these findings were expanded
to include SCARAs as binding targets for PS-ONs when the
ONs are administered in high concentrations.84−86 Since then,
more protein receptors have been identified. These include
stabilin-1 and stabilin-2 which were both found to bind PS-
ONs with high affinity, inducing clathrin-dependent endocy-
tosis.87 Epidermal growth factor receptor (EGFR) has also
been shown to directly interact with PS-ONs, cotrafficking
them alongside EGF into clathrin-coated pit structures.88
Gymnotic uptake is also partly dependent on SIDT2, however
to what extent is unclear yet.89
As far as we know now, protein binding is the principle
association mechanism. It is also important to consider the
roles that plasma membrane lipids play in the ON delivery
process. In association, lipids coordinate various functions by
laterally segregating the membrane proteins into lipid raft
structures.90 The ability of lipid rafts to form these assemblies
of proteins and lipids is critical for internalization to occur.
Other than the PS backbone modification, ON chemistries
involving targeting ligand conjugations have been used to
increase ON association. Since clathrin-dependent endocytosis
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has been identified as a productive uptake pathway,91 many of
these conjugations target membrane proteins known to be
internalized during clathrin-dependent endocytosis. These
include LDL receptor, transferrin receptor, and certain
GPCRs.83
Since the 1990s, researchers have also used lipofection
techniques to improve the cellular delivery of ONs. This is
partially due to the cationic lipids increasing the amount of ON
which becomes associated with the cell membrane.92 Also, it is
also believed that a small percentage of ONs can enter the cell
through stimulated macropinocytosis, a less-regulated albeit
highly coordinated, triggered pathway of fluid-phase endocy-
tosis.93,94
Internalization. After association, internalization of the
ON leads to the entrapment into endosomal vesicles. There
are several routes that this could occur by, but all involve two
main steps: first, the concentration of materials into a distinct
patch on the cell membrane, and subsequently, the protruding
or pinching of the membrane-which causes the membrane bud
inward, becoming an endosomal vesicle.95
Clathrin-mediated endocytosis is the most extensively
characterized internalization pathway for productive ON
delivery. Clathrin was identified in 1975 as a coat protein
comprised of heavy and light chains.96,97 Coat proteins are the
key players in endocytosis as they induce the formation of
specialized membrane patches and sequentially trigger these
patches to bud inward.98 The clathrin-coated membrane buds
are then severed to become endosomal vesicles by dynamin
GTPase in a two-step process.99 Clathrin-mediated endocy-
tosis is a highly selective process, capable of forming complex
vesicles and maintaining precise stoichiometric ratios of the
cargo regardless of the vesicle sizes.100
Other clathrin-independent internalization mechanisms can
also facilitate ON activity. Of these, the most characterized
mechanism is caveolae-mediated endocytosis. Caveolin pits are
invaginations in the cell membrane which are present in many,
but not all, cell types and contain at least one caveolin family
protein. They have been implicated in endocytic uptake, as
well as maintenance of membrane tension and cell surface
area.101 These caveolin pits can endocytose a wide range of
cargo.95 Caveolin pits are dependent on dynamin for vesicle
scission similar to clathrin-mediated endocytosis.
Macropinocytosis is another internalization route which
does not necessitate the association step. Macropinocytosis
involves the ruffling of the membrane to form a protrusion
which then collapses, essentially “swallowing” a volume of the
extracellular environment. While macropinocytosis is an
activated type of endocytosis and therefore requires some
cargo association, the internalized volume is large enough for
nonselected solute molecules to be internalized from the
extracellular environment. Macropinocytosis involves internal-
ization of membrane patches which are much larger than the
other endocytic routes (larger than 1 μm).102
Several internalization pathways may each contribute to
productive ON delivery as all internalization routes converge at
the early endosome. In the case of ON delivery, this results in
the accumulation of ONs into endosomal compartments
regardless of the exact internalization pathway that led them
there. This is to the benefit of nuclear ON delivery considering
endosomal maturation is a process which generally traffics
cargo toward the lysosomes, which are located in proximity to
the cell’s nucleus.
Trafficking. Intracellular trafficking naturally differs be-
tween cell types and remains one of the most important
processes determining the eventual pharmacological activity of
ONs.103 Endocytic vesicles typically fuse with early endosomes
(EEs) after pinching off from the plasma membrane.104 This
fusion is mediated by the class C core vacuole/endosome
tethering (CORVET) complex which localizes to early
endosome membranes.105 Early endosomes may then sort
their cargo inward to late endosomes (LEs) or multivesicular
bodies (MVBs) or recycle cargo back to the cell membrane via
recycling endosomes for exocytosis.106,107 For all cases except
exocytosis, the endosomal trafficking will involve a decrease in
luminal pH as endosomal compartments mature and
eventually converge with lysosomes with an acidic pH between
4 and 5.108
The movement of endosomal vesicles through the cytoplasm
is a highly regulated process, where vesicles attach to motor
proteins in a GTPase-dependent process. In nonpolarized cells,
microtubules are arranged radially, enabling endosomal vesicles
to move bidirectionally along them toward or away from the
nucleus. Kinesin motors are responsible for shuttling organelles
inward along microtubules, while dynein motors transport
them in the opposite direction.109
The Rab protein family, which comprises over 60 GTPases,
determines when and how vesicles should move. Rab proteins
can recruit a wide variety of effector proteins, making them
central to the spatiotemporal regulation of vesicle trafficking by
acting as on/off switches for motors, kinases, tethers, and other
proteins.110 Due to their specific localizations, the Rab proteins
are often used in research as markers for various
endolysosomal organelles. Rab5 is commonly used as an
early endosome marker, while Rab7 is an established late
endosome/lysosome marker.111
The final step within the trafficking process is the
recognition and fusion of vesicles to their targets. The vesicles
must be brought within close enough proximity to meet their
targets in a process called docking. Docking occurs via tether
proteins, which are able to recognize markers on the vesicle’s
surface to determine whether fusion should occur.112 On one
end, tether complexes will interact with Rab proteins on the
vesicle surface, and on the other end they interact with SNAP
receptor proteins (SNAREs).113
There are several protein families controlling the fusion
process, but at its core, the SNARE complex is responsible for
the reaction driving membrane fusion. There are two subsets
which form the complex when they meet: t-SNARE proteins
located on the target membrane and v-SNARE proteins bound
to the vesicle membrane. Formation of the SNARE complex is
an extremely energetically favorable reaction, sufficient to
overcome the energy barrier to membrane fusion.114 It cannot
work alone, however, due to a lack of specificity, and there
exists a wide assortment of factors and regulators, assuring the
vesicles only fuse to their intended targets.115
PS-ONs have been shown to quickly progress from EEs to
LEs with the help of Annexin A-2 (ANXA2).104 ANXA2
colocalizes with PS-ONs in late endosomes, and upregulation
of ANXA2 enhances ON activity. ANXA2 reduction caused
significant accumulation of ONs in early endosomes and
reduced their localization in LEs, ultimately decreasing PS-ON
activity.104 EGFR, mentioned above involved with association,
has also been implicated to assist the endocytic trafficking of
PS-ONs to late endosomes, and interestingly, increased levels
of EGFR correlates with increased PS-ON activity.88
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As the endosomal cargo is trafficked along the endosomal
system, it will proceed through certain points which have been
identified as potential points of endosomal escape.
Endosomal Escape. The endolysosomal network ulti-
mately have three end points. ONs will either be redirected to
the extracellular environment via exocytosis, released into the
cytosol of the cell where they can reach their targets, or
arrested and degraded in lysosomes. In the context of ON
delivery, the exocytic and lysosomal end points can be
considered as nonproductive. The targets for almost all ONs
are generally in the cytosol or the nucleus. The ideal ON
delivery pathways would allow the ONs to “hitchhike” along
the endosomal pathway toward the nucleus and then escape
before reaching the lysosome.
The predominant approaches for encouraging endosomal
escape rely on the acidification of endosomal vesicles that
occurs as they mature from EE to LE to lysosomes. This
acidity is achieved by action of vacuolar-type ATPase (V-
ATPase), an ATP-reliant complex which pumps protons into
the lysosomal lumen.116 The extent of V-ATPase activity may
vary between lysosomes, as lysosomal luminal pH and
composition can differ depending on their cellular location.117
The positioning of lysosomes to the perinuclear region is
determined by the endoplasmic reticulum (ER) protein ring
finger protein 26 (RNF26) and to a lesser extent by Rab34,
which associates to the Golgi apparatus.118−120
In the context of ON delivery, this decreasing pH can be
buffered with an ionizable or amphipathic delivery agent. One
hypothesis, deemed the “proton sponge effect” asserts that
buffering the lumen of late endosomes and lysosomes results in
an osmotic inflow of water into the endosome, which can lead
to engorgement and leakiness due to physical stress on the
membrane.121
Another approach for enhancing endosomal escape involves
exploiting the differences in lipid profiles of the endolysosomal
organelles. For example, cholesterol is abundant in the
membrane of late endosomes, but it is present at very low
levels in the lysosomal membrane.122 LDL cholesterol has been
observed to enlarge endosomes and increase their volume,
which could induce leakage due to mechanical stress.123 After
LDL has been internalized in a clathrin-dependent manner, it
can be released directly from the early endosome, or it can
continue to the late endosome where it undergoes hydrolysis
and the LDL-derived cholesterol egresses from the late
endosome.124
Third, the formation of MVBs is another key point for
leakage to occur. During the transition from endosome (either
early or late) to MVB, inward budding of the endosomal
membrane will occur, resulting in the formation of intraluminal
vesicles (ILVs).125 ILVs, which contain the luminal cargo, can
sometimes fuse with the MVB membrane which they are
contained within, in a process known as back fusion.126 Back
fusion is one possible route for ONs to escape into the cytosol
and the nucleus.
Lysobisphosphatidic acid (LBPA) has been indicated as an
important controller of the fusion cycles of ILVs.127 LBPA is
necessary for the late endosomal membrane to deform and bud
inward, as it does during the formation of ILVs.128 LBPA is a
phospholipid which is only present in LEs, and has been
implicated in controlling endosomal cholesterol levels.129
LBPA-mediated intraendosomal trafficking significantly con-
tributes to productive ON release.130
Escaping the endosome remains the largest barrier to ON
therapy on a pharmacological basis. It is no longer isolated to
the field of ON development. There is promise that delivery
can be enhanced, or entirely rewired with the use of
nanoparticles, both biological and synthetic. Below, we discuss
how nanoparticles are being characterized, engineered, and
utilized for delivering RNA therapeutics.
Figure 3. Endocytic uptake and endosomal escape of ONs. The major identified internalization routes of ONs are clathrin-dependent
endocytosis, clathrin-independent endocytosis, and macropinocytosis. ON is then trafficked sequentially to the early endosome and
sequentially to the late endosome, where it is trafficked to the lysosome or to the multivesicular bodies and exocytosed. Late endosome
membrane remodeling and transition to MVB or lysosome have been indicated as likely points of endosomal escape. Commonly used
endosomal markers are shown. Abbreviations: Rab, Ras-associated protein; EEA1, early endosome antigen 1; LBPA, lysobisphosphatidic
acid; LAMP1, lysosomal-associated membrane protein 1. Figure created in BioRender.
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NANOPARTICLES FOR RNA DELIVERY
In addition to the current repertoire of chemical modifications,
there is a growing focus on developing synthetic and biological
nanoparticles for ON delivery. In this review, we look into two
nanoparticle-based approaches that are used to enhance
delivery: lipid nanoparticles (LNPs) and extracellular vesicles
(EVs).
LIPID-BASED NANOPARTICLES FOR RNA DELIVERY
Sophisticated synthetic delivery systems are designed for
genetic drugs to be used clinically. Lipid-based nanoparticles
can be engineered to package diverse cargo for effective
therapeutic delivery and are currently the most promising
nonviral delivery systems for enabling the clinical potential of
genetic drugs.131−135 The particle structure of the nanoparticle
is dictated by the self-assembled properties of the lipid and
cargo mixtures in the specific buffer conditions chosen.
Broadly, lipid-based particles can be divided into two key
types: liposomes and lipid nanoparticles (LNPs).
Liposomes have a core−shell structure with a uni- or
multilamellar lipid bilayer surrounding an aqueous internal
core. Many investigated drug delivery systems employ
unilamellar lipid vesicles of around 100 nm in size, although
depending on the formulation method a significant proportion
of multilamellar lipid vesicles may coexist, which can impact
cargo loading and delivery.136
LNPs lack the internal aqueous core that defines liposomes
and instead have a lipid-based core whose structure depends
on the lipid and cargo mixtures used.136 In some cases, the
core is highly ordered and the packing of lipids can be
described by specific morphologies such as cubic, hexagonal,
micellar or sponge phases. These are typically interspersed with
either aqueous pockets or water channels. In other cases, the
internal lipid core is less well-defined and is an amorphous
structure. These have been extensively characterized in other
reviews.137−139
The formation of stable LNPs also requires the inclusion of a
stabilizing moiety. The most commonly used stabilizers are
PEG-based polymers and PEGylated lipids. Different stabil-
izers and their effects on morphology, uptake, and toxicity have
already been summarized previously.140,141 Understanding the
lipid structures and their response to local environments is key
to rational design of LNPs, effective cargo loading and its
subsequent delivery.
As described above, the major challenge to implementing
RNA-based gene therapies is the delivery to their intracellular
targets which is limited by their degradation in biological
fluids, and limited tissue targeting and cell penetration.142
Here, we briefly describe LNPs as synthetic nonviral delivery
systems which have the advantages of being easily designed
and manufactured while enhancing the delivery to disease sites
and reducing immune system stimulation.
RNA Encapsulation with Ionizable Cationic Lipids.
Efficient loading of diverse cargo into lipid-based therapeutics
is complex. Small hydrophobic drug molecules can incorporate
into the lipid bilayer while hydrophilic molecules can be
encapsulated in the aqueous environment.143 For larger cargo,
such as proteins and RNA, encapsulation can be less efficient
and a direct interaction between the particle and cargo is
necessary. Electrostatic interactions, where the cargo and
membrane have opposite charges, leads to increased loading
via a charge association. Cargo encapsulation is performed at
low pH where the lipid is protonated and positively charged,
while at physiological pH, its charge is neutral and the LNP
exhibits near-neutral external membrane surface charge. This is
the key particle loading mechanism exploited for LNPs with
RNA cargo.144,145
In 1987, Felgner et al. reported on the formation of
complexes between the cationic lipid DOTMA and plasmid
DNA, which when formulated with DOPE to make lipoplexes
resulted in successful transfection of cells in vitro.146 However,
using cationic lipids results in a surface charge on the LNP, and
it has subsequently been suggested that this may increase
toxicity and lead to rapid surface protein adsorption and
clearance by the reticuloendothelial system (RES), as well as
undesired side effects.147−149
The development of optimized “ionizable lipids” represents
one of the most important factors in the clinical success of
RNA loaded-LNPs. The term ionizable lipid is typically used in
the field to describe amine-containing lipids which are neutral
at pH 7 but become positively charged at lower pH via
protonation of the amine moieties.150 These ionizable lipids
can be used to efficiently encapsulate negatively charged
polymers such as RNA and DNA into LNPs by virtue of charge
interactions between the lipids and the ONs during the initial
formulation step, which occurs below the lipid pKa. Many
studies have quantified particle formation and functional
delivery of ON cargo using ionizable lipids. In some cases,
they are the predominant lipid species, and in others, form
only a percentage of the total lipid mixture. The self-assembled
particle structures formed by the lipid mixtures are driven by
the biophysical characteristics of the lipid mixture and their
interaction with the cargo. There is some evidence indicating
that particle structure may impact cytotoxicity.151 However,
interpretation of these studies is challenging as particle
structure is predominantly tuned via composition and it can
be complex to decouple differences in toxicity due to
composition and structure.
Studies into the chemical structures of ionizable lipids and
lipid-like structures (termed lipidoids) that maximize the
potency of siRNA delivery have systematically varied the
hydrocarbon chain unsaturation, linker moiety, and head-
group.152,153 Replacing the DOTMA trimethylammonium
headgroup with dimethylammonium yields the ionizable lipid
DODMA, with one unsaturated carbon bond per C18
hydrocarbon chain. The level of chain unsaturation seems to
be an important parameter. By varying the level of chain
unsaturation, Heyes and co-workers reported that the most
effective formulations were observed using 1,2-dilinoleyloxy-3-
dimethylaminopropane (DLinDMA) which has two carbon−
carbon double bonds per alkyl chain, and that more or less
unsaturation leads to less effective siRNA gene-silencing in
vitro. They observed that increased unsaturation led to a
decrease in the lamellar (Lα) to inverse hexagonal (HII) phase
transition temperature and therefore increased fusogenicity,
which facilitates endosomal escape. Notably, however, uptake
experiments suggested that despite their lower gene-silencing
efficiency, the less fusogenic particles were more readily
internalized by cells.152
Using DLinDMA as a starting molecule, optimization of the
“linker group” between the hydrophobic hydrocarbon chains
and the hydrophilic headgroup demonstrated that the
introduction of a ketal ring linker resulted in approximately a
2.5-fold increase in potency, with siRNA-LNP formulations
using this resulting DLin-KC2-DMA (KC2) lipid exhibiting an
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ED50 of approximately 0.4 mg/kg (versus 1 mg/kg for
DLinDMA) in non-human primates.153 Further variation of
the headgroup chemistry, and therefore pKa value, showed a
tight correlation between lipid pKa and the ED50 of
corresponding LNP formulations. Jayaraman and co-workers
observed maximum potency at an optimal ionizable lipid pKa
range of 6.2−6.5150 and identified DLin-(MC3)-DMA (MC3),
with a pKa of 6.44, as particularly potent in siRNA-LNP
formulations for gene-silencing in mouse and non-human
primate models.150
LNP formulations using this optimized MC3 lipid (see
Table 2 for structure) have led to potent delivery vectors,
including the FDA-approved siRNA drug patisiran (Onpat-
tro).154 Additional applications have been observed by
Jyotsana et al., who reported on a highly efficient (nearly
100% uptake) and nontoxic MC3 lipid-based LNP formulation
loaded with siRNA targeting the BCR-ABL fusion oncogene
found in human chronic myeloid leukemia cells in vivo.155 This
study demonstrates that fusion oncogene specific RNAi
therapeutics can be exploited against leukemic cells and
promises additional treatment options for leukemia patients.
MC3 can also be used to safely transfect mRNA in order to
express therapeutic proteins. Nabhan et al. have demonstrated
that RNA transcript therapy can be used for the delivery of
therapeutic mRNA to dorsal root ganglia using an MC3-based
LNP system.156 In rat and monkey models, Sedic et al.
reported on the safe profile of MC3-based mRNA-loaded
LNPs which led to hEPO expression and were well tolerated
even above the anticipated efficacious dose levels.157 Ionizable
lipids developed by Harashima and co-workers use the same
DLin tail as MC3 with slight modifications on the amine-
containing headgroup, giving pKa values of 6.5 (lipid YSK05)
and 8 (lipid YSK12-C4).158 Formulations including these
lipids have shown good in vivo delivery of respectively plasmid
DNA to the spleen159 and siRNA to dendritic cells.160
Furthermore, by adjusting the ratio of these lipids in LNP
formulations, they reported tuning the LNP membrane pKa for
targeted delivery of siRNA to liver sinusoidal endothelial cells
in mice.158
Development of the next-generation of ionizable lipids,
which have biodegradable properties such as cleavable linkages
that lead to rapid elimination in vivo, is already ongoing.135 A
key motivation has been to improve biocompatibility and
tolerability while maintaining high potency in vivo.134 Screen-
ing large libraries of lipids and lipidoids synthesized via a
variety of chemical routes has enabled the roles of structural
features in the molecules to be linked to in vitro/in vivo
efficacy. The presence of ester linkages on the lipid tails render
these structures biodegradable thanks to esterase activity in the
intracellular compartment, and they show enhanced liver
clearance versus MC3 in non-human primates.161,162 Ram-
aswamy et al. also reported successful protein replacement with
human recombinant factor IX mRNA in a mouse model of
hemophilia B using an LNP formulation that utilized a
proprietary ionizable lipid with biodegradable tails, ATX-
100.163 Here, introduction of ester groups on the lipidic
backbone, which can be cleaved by esterases at acidic pH,
increased clearance rate with favorable secondary effect
outcomes while maintaining potency in comparison to
MC3.134
Modifications on structures which have showed in vivo
potency for siRNA delivery include tertiary amino alcohols,
where the headgroup alcohol was found to increase activity.164
Moderna has in recent years reported the efficacy of
aminoethanol headgroup-containing lipids with one linear
and one branched alkyl tail, connected via biodegradable ester
linkers to the tertiary amine, for mRNA therapies.161,162,165
One such ionizable lipid structure, SM-102, is a component of
Moderna’s COVID-19 vaccine. The Pfizer/BioNTec “Com-
Table 2. Selected Lipid Structuresa
aThe structures of a few selected commonly used lipids are displayed above. Box 1, ionizable lipid series DLinDMA, DLin-KC2_DMA (KC2), and
DLin_MC3-DMA (MC3). Box 2, lipidoids CKK-E12, OF-02. Box 3, next generation biodegradable ionizable lipids L319, SM-102, and ALC-0315.
Ionizable cationic lipids are characterized by two functional domains: the ionizable headgroup which contains a protonatable nitrogen (red) and the
hydrophobic tail comprising hydrocarbon chains (blue). The structures of lipidoids (examples in box 2) can vary, but generally they also contain
protonatable nitrogens and hydrocarbon tails. Next-generation lipids contain an extra functional domain, the site of biodegradable cleavage (green),
usually in the form of an ester in the hydrocarbon tail. For LNP formulations using these lipids, see Table 3.
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irnaty” COVID-19 vaccine uses a similar structure, named
ALC-0315, with an aminobutanol headgroup.
Anderson and co-workers developed a diketopiperazine-
based ionizable lipid, cKK-E12 (also known as MD1), which
has been used in LNP formulations for cancer immunotherapy
and genome editing.166−168 For LNP delivery of mRNA coding
for human erythropoietin (EPO), the cKK-E12 formulation
potency was superseded by OF-02, which introduced
unsaturated fatty chains, thereby increasing mRNA expression
compared to cKK-E12.169 Further, a biodegradable ester
version of OF-02, named OF-Deg-Lin, was shown to promote
protein expression selectively in the spleen, whereas the
nonbiodegradable OF-02 promoted expression in mouse
liver.170
In other examples, in formulations utilizing libraries of
lipidoids synthesized via Michael addition of primary amines
and alkyl acrylates and alkyl acrylamides171 while alcohol-
terminated lipidoids with amide-linked tails improve cell
uptake, amine-terminated lipidoids with ester-linked tails
impart intracellular delivery by navigating obstacles to delivery
further downstream. Notably, in HeLa cells and a mouse
model, they observed near complete knockdown of firefly
luciferase in siRNA-containing LNPs utilizing mixtures of these
two ionizable lipidoids in a synergistic approach, while LNP
formulations with the individual lipidoid components were
ineffective.172 Another variant ionizable lipid named LP-01
(approximate pKa 6.1), with an amine headgroup and ester-
linked tails, was reported by Finn et al. as part of the LNP
formulation for the co-delivery of Cas9 mRNA and single
guide RNA for transthyretin gene, enabling successful editing
of the mouse transthyretin gene in the liver.173
In another example, the COATOSOME SS-series comprises
two tertiary amines with a range of aliphatic chains, linked by a
disulfide bridge. LNP formulations using these ionizable lipids
have shown efficient intracellular delivery and low cytotoxicity.
The tertiary amine motifs respond to an acidic compartment,
such as endosome/lysosome, resulting in membrane destabi-
lization/fusion and RNA cargo release, and the disulfides can
be cleaved in the reductive environment of the cytoplasm.174
Miao and co-workers reported LNP formulations utilizing
lipidoids synthesized from isocyanides in a one-step, three-
component reaction. They found that, from a library of over
1000 molecules, lipidoids with cyclic amine headgroups, azole
linkers, and unsaturated alkyl tails were the best performing as
mRNA vaccines in tumor models in vivo, by stimulating
adaptive immune cells through the stimulator of interfereon
genes (STING) pathway.175 In a final example, screening of
LNP formulations including lipidoids synthesized by reaction
of epoxides with diamines identified the lipidiod C12-200 as
having good in vivo activity in delivery of siRNA,176 mRNA,177
and also of self-amplifying RNA (saRNA).178 In the latter, the
saRNA is complexed to the surface of the LNPs by incubating
it with already formulated LNPs, instead of traditionally being
incorporated in the formulation mixture, and this was seen to
be enough to prevent degradation.
In addition to the structure of the ionizable/cationic lipid,
the overall lipid mixture composition, i.e., the ratio of ionizable
lipid/cholesterol/phospholipid/stabilizer is crucial for opti-
mized formulations.179 Table 3 summarizes key structural and
formulation optimization studies and details the optimal
formulations for specific cargo including the outcome, size/
and formulation method used to produce the LNPs. The
majority of studies listed in Table 3 use loaded LNPs prepared
with a lipid/nucleic acid charge ratio of 3:1.180 It has been
suggested that the amine/phosphate charge ratio is a key
parameter for cargo delivery, where a critical amount of excess
amino lipid is necessary for maximum endosome destabiliza-
tion. Additionally, PEG-lipid surface coverage and dissociation
rate have a significant impact on circulation times.181
RNA-LNP Activity: Structures and Formation Mecha-
nisms. Optimizing production methods for the controlled
formulation of LNPs is challenging. From an industrial
perspective, samples typically need to exhibit functional and
structural reproducibility, long-term stability, scalability, and
cost efficiency. Many studies have reported optimization of
production methods for laboratory studies to improve the
controlled assembly of RNA-loaded LNPs. Particular chal-
lenges include control of LNP diameter, encapsulation
efficiency morphology, and composition.145,161,167,181,182
The required diameter of LNP formulations designed for
passive targeting will depend on their clinical application. A
100−200 nm diameter LNP is appropriate to get a reasonable
cell uptake. For tumor extravasation and retention, however, a
50−100 nm is more suitable. For targeting the lymphatic
system, e.g., bone marrow, 40−50 nm diameter would be a
pertinent choice. Considering the size of low-density lip-
oproteins made in the liver (about 20 nm), for a long-
circulating LNP system, a 20−30 nm diameter size will allow
access to most locations in the body, except perhaps the brain
and muscle. Therefore, control over the particle size is crucial
for clinical success.
Tuning the particle size can be achieved using microfluidic
formulation and by precisely controlling fluid flow rates,
allowing different size distributions to be achieved for identical
particle compositions. Changing the scale of formulations may
affect their properties, requiring expensive and time-consuming
process development. It is possible to form LNPs using
numerous techniques including sonication, agitation, homog-
enization, the spontaneous vesicle formation method,
preformed vesicle method, and microfluidic mixing.131,137,183
The first three techniques necessitate cargo loading post-LNP
formation as the harsh conditions can degrade sensitive cargo
such as RNA. With these considerations, the majority of LNPs
loaded with ON cargo are currently formulated using the
spontaneous vesicle formation method either in bulk or with
an automated mixer with two inputs. More recently, the mixing
is commonly performed on a microfluidic chip.
In a microfluidic chip, one input channel injects the lipids
used in the formulation, typically the ionizable lipid,
cholesterol, and some helper lipids such as phospholipids
(e.g., DSPC, DOPC) and PEG-lipids which are dissolved in
ethanol, and the other channel injects the nucleic acid which is
formulated in aqueous buffer at pH 4. The rapid mixing of the
solvent and aqueous mediums drives the self-assembly of lipid
structures. Recently, many experimental approaches have been
employed to optimize siRNA loaded LNPs formulated via
microfluidics.184 In many cases, the resulting LNPs are highly
dependent on the formulation conditions used and subsequent
dialysis steps. At a pH below its pKa, the ionizable lipid is
positively charged, and therefore, at pH 4, there is an
electrostatic interaction between the negatively charged RNA
and the lipid structures formed which drives an association
between them. At pH 7.4 the ionizable lipid is above its pKa
and therefore no longer positively charged. After mixing of the
lipids and cargo in the microfluidic chip, the solution is
subjected to a dialysis to remove the ethanol and increase the
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pH from 4 to 7. This pH change and the removal of ethanol
induces structural changes in the particles and drives the
formation of the resulting LNP.145 The proposed LNP
formation mechanism is vesicle fusion induced by the
increased pH during the dialysis step and therefore decrease
in the charge on the ionizable lipid. Calculations suggest that
for every LNP observed after dialysis at pH 7.4, approximately
36 of the positively charged vesicles formed at pH 4 need to
fuse as the pH is increased.145 By understanding this process,
lipid composition can be revised in order to optimize LNP
stability and performance.
Understanding the assembly mechanisms of RNA loaded
LNPs is crucial to optimizing formulations. An early
mechanistic study used molecular-modeling approaches, cryo-
transmission electron microscopy, 31P NMR, membrane fusion
assays, and density measurements to study mixtures of
DLinKC2-DMA/DSPC/Chol/PEG-lipid (40/11.5/47.5/1
mol %). The results suggested that siRNA-LNP systems have
a nanostructured core consisting of a periodic arrangement of
inverted micelles with aqueous cores, some of which contain
siRNA duplexes. The proposed formation involved three key
stages; first, rapid mixing between the aqueous siRNA phase
and the lipid ethanol phase, second, the association of cationic
lipid with siRNA to form hydrophobic nucleating micellar
structures, and third, the coating of the nucleating structures by
remaining lipids (potentially the PEG-lipids) as they reach
their solubility limits in the ethanol/water system.185 Further
studies have shown that LNP−siRNA systems can exist in a
continuum of bilayer and nanostructured micellar structures
where the morphology depends on the lipid composition and
siRNA content. As the DLin-KC2-DMA content increased
beyond 70 mol % siRNA encapsulation efficiencies decreased.
This effect was even more pronounced for formulations
containing higher percentages of PEG-lipid. Proof of concept
data also demonstrated encapsulation of mRNA, plasmid
DNA, and gold nanoparticles into LNP systems using
microfluidic formulation techniques.186
More recent studies of lipid mixtures loaded with siRNA and
characterized using cryogenic transmission electron micros-
copy and small-angle X-ray scattering at clinically relevant
siRNA content levels have proposed a revised LNP structure
which includes a combination of siRNA-bilayer structures and
an amorphous core. Based on structural observations where
the size of the amorphous LNP core depends on the amount of
ionizable lipid (20−50 mol %), the amorphous core appears to
be enriched with the ionizable lipid.145 The effect of mRNA on
the structure of MC3-based LNPs with encapsulated mRNA
has also been reported. In a small-angle scattering study,
Lindfors and co-workers observed a disordered inverse
hexagonal structure in mRNA-loaded LNPs which was absent
in unloaded particles. The also reported localization of the
lamellar phase lipid DSPC to particle surfaces180 and showed
that both size and particle surface structure has a significant
effect on intracellular protein production in vitro.
Experiments demonstrate that increasing the PEG content
up to 5 mol % of the LNP by weight decreases the particle size
(27−117 nm), and it has been suggested that the LNP surface
is enriched in PEG-lipid.145,181 Consideration of the amount
and type of PEG-lipid is also crucial for rational design of RNA
loaded LNPs. The PEG-lipid is essential to produce a stable
LNP population with low polydispersity. However, short chain
PEG-lipids are currently preferable to promote shedding of the
steric barrier following IV administration to maximize hepatic
gene-silencing in vivo. Studies using lipid compositions of
MC3, distearoylphosphatidylcholine, cholesterol, and PEG-
lipid to quantitate hepatic gene-silencing showed increasing the
concentration above 1.5 mol % substantially compromises
hepatocyte gene knockdown for PEG-lipids with longer chains
(C18) but not for shorter chains (C14 and C16). This is
attributed to an increased PEG-lipid desorption time in vivo for
C18 compared to C14.187
The amount of PEG-lipid also impacts the LNP sizeas
mentioned previously, the effect of particle size on activity is
crucial for certain applications. By varying the amount of PEG-
lipid content, particle size can be controlled, with smaller LNPs
being formulated at high ratios of PEG-lipid.180,181,185 By
altering the PEG-lipid composition, LNP-siRNA particles
formulated to have a mean diameter of 78 nm showed
maximum FVII gene-silencing in vivo.181
While the size is controlled by the PEG-lipid content, LNP
systems that do not contain enough DSPC to cover an external
surface monolayer will incorporate additional cholesterol and/
or ionizable lipid in that monolayer, thus disturbing the
activity. It was shown that siRNA-LNP systems containing 10
mol % of DSPC exhibit maximum activity for a size of 80 nm,
which suggests that to obtain smaller systems with optimized
activity, higher levels of DSPC should be incorporated.181 This
was confirmed in both human adipocytes and hepatocytes,
where protein expression levels for 130 nm mRNA-LNP
systems differed as much as 50-fold depending on lipid
compositions with a constant DLin-MC3-DMA/Chol molar
ratio. The results suggest that some of these differences may be
attributed to changes in surface composition of the particles
and the impact this may have on the ability of LNPs to fuse
with the endosomal membrane.180,181
The proportions of different lipid species in optimized RNA-
LNP systems may vary according to the particular ionizable
cationic lipid employed (see Table 3). This expands
considerably the possible lipid composition of an LNP system
but mostly challenges researchers to find the optimal
combination for a particular application. On-going efforts are
put on using advanced approaches such as high-throughput
screening methods and computer-assisted drug formulation, as
well as implementing digitalization and artificial intelligence for
developing personalized nanomedicine.
Biological Interactions: PEG Shedding and the
Protein Corona. In biological media, LNP dispersions will
interact with the numerous biomolecules present. The exact
nature of this interaction and the impact on functional delivery
will undoubtedly be complex and systematic studies are
needed. It is possible that serum proteins adsorb on to the
surface of LNPs which could trigger uptake by surrounding
macrophages (e.g., Kuppfer cells) or dendritic cells. The PEG-
lipid is crucial to maintain the size and stability of the LNPs
before administration and any PEG molecules that are present
on the particle surface will also minimize in vivo serum protein
adsorption. This will facilitate access to tissues other than
phagocytes. However, if the PEG-lipid is not optimized for the
application and lipid composition it can inhibit cellular uptake.
It had been observed that the presence of a long-lived PEG-
coating (i.e., PEG molecules with C18 or C20 lipids anchors)
can dramatically reduce RNA activity.181,187,188 To avoid this,
the PEG-lipids have to date mostly been designed to partly
dissociate from the LNPs following injection. It is thought that
this enables access to the LNP surface and therefore
interactions with the biological environment and the target
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cells. This phenomenon is called “PEG shedding”. NMR
studies have shown that the rate of “PEG shedding” is inversely
proportional to the lipid hydrocarbon chain length, meaning
that formulations with shorter PEG-lipids shed more than
those with longer tails.181,189 Inhibition of cellular uptake and
immune response effects were observed by using a C14 anchor
PEG-lipid which sheds off from the surface in few minutes
postinjection.187,190 The mechanism behind this process and
the proteins involved remain obscure; however, it is possible
that a synergy between PEG shedding and coating of the RNA-
LNPs by biomolecules in the surrounding medium, i.e.,
coronation, is essential to maintain particle stability, cellular
uptake, and functional response.191
Coronation, or protein corona formation, is described as the
protein adsorption layer that forms and defines the biological
“identity” of a particle as well as mediates further interactions
between the particles and the biological environment.192−194
Protein corona studies provide molecular level insight into
mechanisms of cellular recognition, uptake, and intracellular
destiny of particles.195 Among the different classes of adsorbed
biomolecules (e.g., proteins,196 lipids,197 carbohydrates,198,199
and metabolites200), the apolipoprotein ApoE, involved in the
metabolism of fats in the body, has shown to play a crucial role
for LNP uptake in hepatocytes.181,201 LNP-siRNA gene-
silencing activity was significantly decreased in an ApoE
knockout mouse model (ApoE−/−), and activity could be
rescued by preincubating the particles with ApoE before
administration. In a low-density lipoprotein receptor knockout
model (LDLR−/−), LNP-siRNA formulations displayed less
gene-silencing activity (leading to higher ED50 values) than in
wild-type animals. LNP activity could be rescued through
addition of a multivalent targeting ligand, N-acetylgalactos-
amine (GalNAc), for the hepatocyte asialoglycoprotein
receptor, thereby promoting internalization through an
alternative endocytic route.202,203 Authors concluded that
ApoE association with siRNA-LNP systems plays a major
role in triggering LNP uptake into hepatocytes by clathrin-
mediated endocytosis via the LDL receptor. These observa-
tions are in line with a previous study by Gilleron et al.
reporting that uptake of LNPs in vitro occurs via macro-
pinocytosis and clathrin-mediated endocytosis.204 In this study,
50% reduction of LNP uptake upon downregulation of the
clathrin heavy chain-1 was observed and knockdown of the
macropinocytosis regulators CTBP1, Rac1, Rabankyrin-5 (but
not Cdc42) or the use of EIPA, a pharmacological inhibitor of
macropinocytosis, led to a 60% and 70% decrease in LNP
uptake in HeLa cells, respectively. Downregulation of caveolin
1 did not modify LNP uptake. In the same cell model but using
a different cationic lipid to formulate the LNP, Sahay et al.
reported that downregulation of Cdc42 and Rac1 led to 80%
decrease in LNP uptake, whereas inhibition of clathrin heavy
chain-1 and caveolin-1 had little impact on LNP entry.205
Together, these studies highlight areas in the design of LNP,
which need further optimization and understanding to achieve
efficient intracellular delivery.
Since LNP delivery efficiency is influenced by the formation
of a protein corona in biological media, one may expect that a
healthy individual or a patient suffering of a pathology affecting
the serum composition, will have different serum-protein
diversity and concentration which could possibly affect the
protein-corona composition of LNP and thus alter their
activity in vivo, as observed for PLGA nanoparticles.206 In
addition, it is important to note that lipid self-assembly and
therefore LNP morphology is driven by biophysical parameters
including composition, temperature, pressure, electrostatics
and lipid packing which have already been extensively reviewed
and are therefore not addressed here.207−209 Therefore, the
morphology and functional response of an RNA-LNP system
administrated into a patient with abnormal body temperature
(e.g., fever or low-body-temperature-related syndrome) may
differ (e.g., protein-corona formation and delivery efficiency)
when compared to a healthy volunteer. To date, LNPs have
shown efficient delivery of RNA to the liver using passive
cellular targeting (size control and protein adsorption).
Compositional variations in LNPs have been demonstrated
to enhance LNP accumulation in the lung and spleen;210
however, delivery to other organs remains challenging. Like
liposomal systems, LNPs can take advantage of “natural” and
synthetic targeting processes to actively reach specific tissues
and cells. The main strategies rely on proteins, peptides or
natural ligands, antibodies or antibody fragments, as well as
aptamers. Antibody-mediated targeting has demonstrated
success in gene-silencing with LNP systems. As an example,
Rameshetti et al. used an anti-CD4 monoclonal antibody as a
targeting moiety on LNP and showed specific binding, uptake
and CD45-silencing in murine CD4 positive T lymphocytes
following intravenous administration.211 In the study, a dose of
1 mg/kg siRNA, lower than other nontargeted systems to
leukocytes, was effective in silencing T-cells in the blood,
spleen, bone marrow, and inguinal lymph nodes. It was also
demonstrated that two CD4 positive T-cell populations exist,
whereby internalization of the targeted LNPs was observed
only by the CD4 low-expression level population, leading to
69% CD45 knockdown, while localization of LNPs on the
surface of the CD4 high-expression level population did not
alter CD45 expression. For B-cell malignancy, Weinstein et al.
designed an anti-CD38 monoclonal antibody-coated LNP to
specifically deliver encapsulated siRNA against cyclin D1 in
mantle cell lymphoma cells.212 The study showed that
treatment induced gene-silencing, suppressed tumor cell
growth and prolonged survival of mice. Hyaluronan is a
natural ligand of the CD44 receptor, which is often
overexpressed on the surface of various cancer cells. Cohen
et al. have shown that local delivery of hyaluronan-coated
LNPs containing siRNA for PLK1 specifically target CD44
cells in a murine glioma model.213 The treatment induced
internalization of the LNP, robust PLK1-silencing, and cell
death of glioma cells prolonging survival of animals. It seems
reasonable to wonder whether the protein corona confound
the targeting of LNP with specific ligands coated on their
surface and if the surface functionality of LNP is preserved in
the presence of a protein corona. Nevertheless, it remains
possible to control on purpose the corona composition. Zhang
et al. have provided an elegant example whereby retinol-
conjugated polyetherimine nanoparticles selectively recruit
retinol binding protein 4 in its corona, enabling targeted
delivery of antisense ONs to hepatic stellate cells.214
Intracellular Trafficking and Endosomal Escape. Upon
internalization, cargo is sequentially transported through early
endosomes, late endosomes, and lysosomes.215 The various
stages of transport can be evaluated by the time-dependent
colocalization with specific markers such as EEA1, as well as
Rab5, for early endosomes, and Rab7/9 or LAMP-1 for late
endosomes and lysosomes. It is believed that an efficient LNP-
RNA transfection relies on an early and narrow endosomal
escape window prior to lysosomal sequestration and/or
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exocytosis. In their study, Gilleron et al. have explored the
biogenesis and maturation of LNP-containing organelles.
Following injection of mice with LNP composed of ionizable
lipid, cholesterol, DSPC, and DMG-PEG with gold particles
conjugated-siRNA, they estimated that only 1−2% of
internalized siRNA was released from moderately acidic
compartments sharing early and late endosomal characteristics,
which nevertheless lead to a significant knockdown.204 Sahay et
al. have tracked the intracellular transport in HeLa cells of
similar LNP system (with different cationic lipid) loaded with
siRNA. They estimated that 70% of the siRNA underwent
endocytic recycling via late endosomes and lysosomes and
concluded that efficiency of siRNA delivery by LNP is limited
by endocytic recycling.205 To block these events and thereby
increase opportunities for endosomal escape, Wang et al. have
inhibited the Niemann Pick type C1, a late endosomal/
lysosomal membrane protein involved in endosomal recy-
cling.216 The study revealed that the presence of the inhibitor
NP3.47 caused 3-fold or higher increases in accumulation of
LNP-siRNA in late endosomes/lysosomes and the gene-
silencing potency of LNP siRNA was enhanced up to 4-fold
in the presence of NP3.47. This is an attractive strategy to
enhance the therapeutic efficacy, however, it is believed that a
deep understanding of what orchestrates the RNA escape from
endosomes will aid the design of safe and efficient LNP
systems. It has been shown ex vivo that cationic lipids can
exhibit the ability to induce nonbilayer structures in lipid
systems containing anionic phospholipids.217
Biophysical studies where the behaviors of biological
particles (e.g., cellular organelles or LNPs) and membrane-
membrane interactions are mimicked can provide insights into
mechanisms driving LNP functionality. These approaches
enable control of the LNP environment (e.g., hydrodynamic
flow, controlled pH, protein-corona formation) to track their
motion via surface-sensitive optical imaging, enabling deter-
mination of their diffusion coefficients and flow-induced drifts,
from which accurate quantification of both size and emission
intensity can be made.218 In cells, the two methods that
provide robust confirmation of endosomal disruption are
transmission electron microscopy and cellular fractionation,
but these methods are not amenable to rapid, high-throughput
analysis. In contrast, fluorescent microscopy allows to detect
endosomal rupture events in living cells with high-content
imaging. After the role of Galectin 8, a cytosolically dispersed
protein, in innate immunityin which it functions to detect
disrupted endosomes due to high-affinity binding with glycans
selectively found on the inner leaflet of endosomal
membraneswas discovered,219 Wittrup et al. used cytosolic
galectins (Gal1, Gal3, Gal4, Gal8 and Gal9) to monitor
endosomal disruption of LNP in living cells.220 They reported
that the appearance of Gal8 positive spots temporally coincides
with the cytosolic delivery of fluorescently labeled siRNA from
LNPs. More recently, Kilchrist et al. have established the utility
of Gal8 subcellular tracking for the rapid optimization and
high-throughput screening of the endosome disruption
potency of intracellular delivery technologies.221 Galectins
are 15 members family of carbohydrates with widespread
functions and expressions across cell types. The tracking of
endosomal escape events requires the development of live-cell
imaging assays which can be used to screen for LNP efficiency
on a large diversity of cells. A 30-cell line LNP-mRNA
transfection screen identified three cell lines having low,
medium, and high transfection that correlated with protein
expression when they were analyzed in tumor models.
Endocytic profiling of these cell lines identified major
differences in endolysosomal morphology and pH, localization,
endocytic uptake, trafficking and recycling.222 The endocytic
profiling and monitoring of endosomal escape events are an
important and challenging preclinical evaluation step to
support the success of nucleic acid delivery systems and
improve their translation to clinical trials.
EXTRACELLULAR VESICLES FOR RNA DELIVERY
Extracellular vesicles (EVs) consist of a heterogeneous family
of nanosized vesicles (overall 40−2000 nm) including
exosomes, microvesicles (MVs), and apoptotic bodies. EVs
are naturally released by all cells into the extracellular
environment and body fluids, playing key roles in different
processes including antigen presentation and intercellular
communication. EVs are able to transfer molecules from
donor cells to recipient cells through the extracellular
environment and the bloodstream.223−226 The field of using
EVs for drug delivery was ignited in 2007 when Valadi et al.
demonstrated that exosomes from murine mast cells could
transfer material to human mast cells, resulting in the presence
of exogenous murine protein in the recipient human cells.227
Since then, myriad publications have demonstrated the utility
of using EVs derived from different sources for delivery of
various RNA species.
While LNP-based therapeutics have already reached the
clinic, EVs are not far behind. Recent developments in the EV
field have led to numerous clinical trials involving EVs as
targeted therapeutics.228,229 As discussed herein, EVs are
complex, multicomponent systems, and therefore, their
development as a next-generation drug delivery platform
requires expansive elucidation. To this end, the EV field has
grown exponentially in recent years. In this section, the
engineering and production methods of EVs are outlined with
a focus on using EVs to deliver RNA.
EV Biogenesis. Whether in vitro or in vivo, cells constantly
produce, internalize, and recycle biomolecules and nano-
particulate species including EVs. Several subpopulations of
EVs exist and can be classified by various criteria such as their
cargo composition, their size and density, or, most commonly,
their biogenesis.
The goal of EV biogenesis studies is to characterize how EVs
are formed via different pathways and how each pathway
determines the EV composition and physical character-
istics.230,231 The two general types of EVs, based on biogenesis,
are microvesicles (MVs), which bud from the plasma
membrane, and exosomes, which originate from the endocytic
pathway. Exosomes are formed through the release of
intraluminal vesicles (ILVs) from within multivesicular bodies
(MVBs). These can be further classified into smaller
subpopulations of EVs based on size, density, and the presence
or absence of EV biomarkers. Due to MVs and exosomes being
formed in different cellular locations and loaded via different
packaging machinery, their luminal cargo differs in composi-
tion.231
The biogenesis of EVs is a heavily discussed subject within
the EV research field. Years of research have brought to light
numerous, difficult-to-elucidate pathways of EV biogenesis,
which are heavily interwoven with other cell functions. For
example, exosome biogenesis can be broadly divided into
endosomal sorting complex required for transport (ESCRT)-
independent or ESCRT-dependent pathways. ESCRT and its
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associated proteins, such as ALIX, syntenin, syndecan, and
TSG-101, have been implicated in ILV formation and exosome
biogenesis to varying degrees between cell types. Do to their
role in EV biogenesis, these proteins have historically been
used as EV biomarkers. However, studies in mammalian cell
culture have revealed that a complete disruption of ESCRT
function, and therefore the interactions of these proteins, does
not abolish ILV formation.232 Similarly, ALIX depletion
decreases but does not abolish EV production but rather
shifts the heterogeneity in protein composition of the
produced EVs.233−235 These findings imply that numerous
pathways for exosome secretion exist with some interdepen-
dencies, but exosome production is not completely dependent
on any single pathway.
The fact that various EV-packaging machineries exist
coincides with the fact that certain EV subpopulations can
induce differential effects in recipient cells.236,237 Together,
these imply that certain subpopulations may be better suited
than others for some therapeutic strategies. For example,
subpopulations can exhibit differential organ biodistribution
profiles in vivo.238,239 It also suggests that certain subpopula-
tions of EVs may contain more relevant biomarkers than other
subpopulations and should therefore be preferentially isolated
for analysis in diagnostic settings.240 The functional differences
between EV subpopulations are not yet fully characterized, and
there remains a strong focus in the EV field to better
understand EV heterogeneity at the single vesicle level.
Despite the complexity of EV biogenesis, effective
approaches to load EVs with specific cargo have been
developed. These engineering strategies often utilize the
proteins which contribute to endogenous EV biogenesis,
such as those mentioned above. In the context of RNA
delivery, EV engineering approaches seek to preferentially load
RNAs into EVs. This can be accomplished through
endogenous of exogenous loading approaches.
Endogenous Loading of RNA into EVs. Several groups
have attempted to map the endogenous RNA profiles of EVs
from different species, organs, disease states, and cell types. To
date, almost all types of RNA have been found in isolated EVs
in both functional and fragmented forms, including miRNA,
rRNA (rRNA), long noncoding RNA. The majority of RNA
present in EVs is between 20 and 200 nucleotides in size.
Several groups have also found that EVs, particularly those of
cancer origin, contain full length, functional mRNA.241−243
Almost every study mapping the RNA profiles of EVs has
revealed that certain RNA species are differentially loaded into
EVs. It appears that in some instances, the selection of certain
RNAs is due to a specific RNA-sorting machinery, and in other
instances this differential loading is simply a biproduct of
unspecific, unrelated processes.244
It is currently believed that EVs carry approximately half of
the total circulating RNA in plasma.245,246 This includes coding
and noncoding RNA such as miRNA, mRNA, tRNA, and
others. Additionally, the different populations of EVs contain
distinct RNA profiles, with MVs having an RNA profile most
closely resembling the transcriptome of the producer cells
while exosomes are enriched in miRNA.247 The foremost goal
of endogenous RNA loading is to take advantage of the
inherent selective enrichment of the desired RNA into EVs.
This can be accomplished by either a passive or an active
loading process. Passive endogenous loading involves using a
construct to overexpress the desired RNA which is then loaded
into EVs via the cells’ own mechanisms. In this approach, the
overexpression vector functions to stoichiometrically increase
RNA loading without the need for other vectors which alter
RNA loading through molecular interaction. Active endoge-
nous loading, on the other hand, involves the implementation
of a recombinant fusion construct which usually contains an
RNA-binding domain (RBD) fused to an EV protein.248 Active
endogenous loading has been used to substantially increase the
number of target mRNA loaded into EVs.249
Active endogenous loading of mRNA must utilize some
RBD which recruits the desired RNA into EVs. Currently,
there is a strong focus in the EV field to identify RBDs
responsible for the endogenous sorting of specific RNA into
the EVs.250 So far, these studies have revealed specific RNA-
binding proteins (RBPs) such as MVP (major vault protein),
YBX1 (Y-box protein 1), and sumoylated hnRNPA2B1
(heterogeneous nuclear ribonucleoprotein A2/B1).251,252 The
presence of endogenous RBPs implies the existence of protein-
binding motifs on the mRNA which is enriched in EVs.
Separately, this was confirmed in the identification of a
zipcode-like 25 nucleotide sequence in the 3′-untranslated
region (3′UTR) of mRNAs enriched in MVs compared to
their parental cells.253
Active endogenous loading is a well-established technique to
load exogenous proteins into EVs. For example, in a screening
study comparing several GFP-tagged EV sorting domains,
Corso et al. found that transient overexpression of CD63-GFP
in the EV-producing cells yielded fluorescent EVs which
contain 40−60 GFP molecules per vesicle.254 Additionally,
approaches which use non-human RNA-binding domains exist.
For example, Wang et al. developed a platform utilizing the
HIV-TAT peptide to selectively load mRNA into MVs for
functional delivery.255 The number of RBDs and EV proteins
which are being utilized for active endogenous mRNA loading
is continually increasing.
Apart from mRNAs, platforms for loading small RNA
species into EVs are being developed. Passive endogenous
loading of miRNAs can be achieved by use of a miRNA
overexpression construct. For example, it has been shown that
HEK293 and COS-7 cells, upon transfection with a plasmid
coding for several miRNAs (e.g., miR-16, −21, −143, −146a or
−155), release exosomes containing these specific miRNAs.
Importantly, these exosomes could deliver the miRNAs into
recipient cells, leading to mRNA-silencing.256 Similarly, pre-
miR-451 has been identified as a pre-miRNA which is highly
enriched in extracellular vesicles. As long as the hairpin
structure of the pre-miRNA is conserved, the miRNA target
sequence can be altered.257 By inserting a desired target
sequence into the pre-miR-451 hairpin structure, EVs were
produced which could functionally deliver the pre-miRNA in
an efficacious manner, demonstrating this approach as an
effective passive endogenous method of loading functional
small RNA into EVs.
One of the biggest experimental challenges with using
endogenous EV loading is the inability to prevent carry-over of
plasmid DNA, viral RNA, or translated protein into the
produced EVs. Overexpressing mRNA is always accompanied
by increased protein translation in the EV-producing cells. It is
then difficult to discriminate between RNA-mediated effects
and protein-mediated effects in the recipient cells. de Jong et al.
approached this issue with development of a Cas9-based
reporter system which relies on EV transfer of sgRNA, enabling
measurement of EV RNA transfer on the single-cell level.258
While there is a focus within the EV field to address this
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challenging aspect of endogenous RNA loading, there also exist
techniques to load EV cargo in a highly selective manner
through exogenous loading.
Exogenous Loading of RNA into EVs. While the
endogenous approaches rely on the production of cargo-
loaded EVs, the exogenous approaches focus on loading cargo
into EVs once the EVs are already produced and isolated. For
some EV cargo which is hydrophobic, this can be achieved
simply by co-incubation with EVs. In 2010, Curcumin (an anti-
inflammatory therapeutic) was successfully loaded into EVs
after co-incubation with isolated EVs at room temperature (22
°C) for 5 min. These EVs were able to protect the curcumin as
well as to improve its solubility and functional efficiency in
vivo, suppressing the inflammation in mouse models.259
However, cargo which is hydrophilic must be loaded in a
strategic manner. This often occurs via harsh physical methods
which can compromise EV integrity, decrease immune-
compatibility, and induce EV and cargo aggregation or
degredation.260,261 Electroporation is the most common
method to date, in which EVs are electrically stimulated
while in a solution of the cargo. The EV membrane
spontaneously forms pores in which the cargo can enter the
lumen.262 This has proven an effective method for loading
functional siRNA.263,264 In 2018, EVs electroporated with
either miR-125b-ASO or Cas9 mRNA + sgRNA were able to
functionally deliver their cargo.265 When the EVs containing
the miR-125b-ASO were delivered in vitro to leukemia cells or
systemically injected in mouse models, the miR-125b
expression was reduced; at the same time, EVs loaded with
Cas9 mRNA were transferred, simultaneously with gRNA
targeting miR-125b, to leukemia cells (MOML13), miR-125b
expression was reduced by 98%.
Another, more recent, exogenous RNA loading technique is
to co-incubate isolated EVs with cholesterol-conjugated
siRNAs (cc-siRNA). After optimizing the protocol for siRNA
loading via this method, EVs achieved concentration-depend-
ent silencing of human antigen R (HuR).266 Similarly, a
hydrophobically modified siRNA (hsiRNA) targeting Hun-
tingtin (HTT) mRNA could be functionally loaded into
exosomes via co-incubation. Reduction of HTT mRNA was
observed after the EVs were injected to mouse primary cortical
neurons.267 Other methods of exogenous RNA loading include
EV transfection, sonication,268 extrusion,269 and liposome-EV
hybrid particle formation.270,271
A combination of both endogenous and exogenous methods
can also be applied successfully.272 For example, targeting
proteins can be endogenously incorporated to the EV
membrane, and then RNA can be loaded to the isolated EVs
via exogenous methods. This was demonstrated by Alvarez-
Erviti et al. by means of endogenously loading Lamp2b-fusion
constructs onto EVs and then sequentially loading the EVs
with siRNA via electroporation.273 Similarly, EVs engineered
with Lamp2b-Rabies Virus Glycoprotein (RVG) and loaded
with siRNA were successfully delivered to mouse brain via
intravenous injection.264 These combination engineering
strategies are being continuously optimized and show promise.
EV Fate and Cargo Delivery. The fate of EVs in
circulation is believed to be determined by factors such as EV
size and the display of surface components which may
influence recognition of the EVs by cells. The extents to
Figure 4. RNA-loading approaches for EVs. EV cargo-loading can be broadly classified as passive endogenous loading, active endogenous
loading, or exogenous loading. Endogenous pathways involve transfection or transduction of genetic material into the EV-producing cells. In
passive endogenous loading, an RNA overexpression construct leads to stochastic EV loading of an abundantly transcribed RNA. In active
endogenous loading, an additional construct comprised of an EV marker protein and an RBD capture the target RNA and shuttle it to EVs
during their biogenesis. Exogenous loading occurs after EVs have been isolated and involve physical or chemical techniques to insert RNA
into the EV lumen. Abbreviations: RBD, RNA-binding domain; MVB, multivesicular body. Figure created in BioRender.
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which EV uptake is determined by EV characteristics or by
attributes of the recipient cells remains incompletely
characterized, and there are studies suggesting the importance
of both. Generally, the mechanisms of EV uptake can be
broken down into 3 steps: targeting, internalization, and cargo
delivery.
Targeting to the acceptor cell refers to the initial contact and
capture of the EV by the acceptor cell. Targeting can occur on
a tissue-specific level and a cell-specific level. In regard to tissue
targeting, EVs have been shown to have a short half-life in
circulation in mice when administered intravenously, with
organs showing peak EV internalization at 5 min post-
injection.239 The organs with the highest EV signal were the
liver and spleen.
On the cellular level, several proteins present on both EVs
and the surfaces of the acceptor cells have been implicated in
EV targeting and capture. These including lectins, proteogly-
cans, integrins such as ITGB3, and T-cell immunoglobu-
lins.274−277 Additionally, exogenous targeting proteins can be
utilized to increase or decrease EV targeting to a desired cell
type or tissue. As mentioned above, RVG can increase EV
targeting to mouse brain.264 Conversely, EVs which display
CD47 are capable of evading macrophage and monocyte
detection, which beneficially increases the EV time in
circulation.278
The second step, internalization, is also determined both in
part by characteristics of the EVs and the acceptor cell types.
Early studies of EV internalization identified macropinocytosis
as a route of internalization, and since then several other
uptake pathways have been identified including receptor-
mediated endocytosis and filopodia-recruitment.279−281 To
date, there are no specific proteins which have been shown
completely sufficient and necessary to initiate EV internal-
ization.282 However, specific factors have been identified as
strongly influencing EV internalization. For one, heparin
sulfate proteoglycans (HSPGs) that reside on the acceptor
cells are able to bind cancer-derived EVs and the level of
HSPG-dependent EV uptake is strongly relevant to the
biological activity of the EVs.277 In line with this, heparin
has been shown to block functional EV transfer between
cells.283 Additionally, integrins on the surface of EVs from
tumors have been implicated as a key component driving the
uptake of these EVs.284 Together, these findings implicate both
positive and negative uptake-regulating factors on the surface
of EVs.
The third step, cargo delivery, is dependent on the ability of
the EV membrane to fuse with the membrane of the
endosomal compartment it is trafficked into. By achieving
this fusion, endosomal escape of the EV cargo can be initiated.
EV Zeta-potential partially determines membrane destabiliza-
tion and subsequent membrane fusion. The zeta potential of
EVs is influenced by pH and the valency of surrounding
ions.285 It follows that as internalized EVs are shuttled along
the endosomal system, the decreasing pH reduces EV
membrane stability, encouraging membrane fusion. The exact
endocytic organelles in which this occurs is not fully
elucidated.
The lipid composition of the EV membrane and the
endosomal membrane are also proposed to influence cargo
delivery. Endosomal membranes are constantly undergoing
remodeling and recomposition as endosomes mature. The
dynamic nature of the endosomal membrane is crucial to EV
cargo delivery. Endosomal remodeling is dependent in part on
the presence of cholesterol and phosphatidylserine, both of
which are present endogenously to EV membranes.286−289 The
presence of these membrane components may play a crucial
role in EV-endosome membrane fusion. Fitting with this, it has
been demonstrated that EV cargo delivery is diminished by
blocking EV phosphatidylserine.290
Many early studies of EV uptake fall short of demonstrating
cargo delivery, and instead quantitate only EV internalization.
This is usually based on a fluorescent readout which can
quantitate uptake events per cell.291 However, even if the
fluorescent signal is coming from within the cell, it is still
unknown if the signal is coming from a functional compart-
ment of the cell such as the cytosol or nucleus, or if the cargo
has been arrested in the endosomal system. Recent work has
focused on developing approaches to quantitate cytosolic or
nuclear delivery of EV cargo. This can be accomplished by
means of complementary subunit reporter systems, in which a
nonfunctional protein subunit is loaded into EVs and the
complementary subunit is expressed in the cytosol of the
recipient cell.292 This has led to the development of strategies
which encourage endosomal escape of EV cargo.
Another recently developed strategy for endosomal escape of
EV cargo is to engineer EVs to display fusogenic proteins or
peptides on their surface. One of the most promising proteins
is the G glycoprotein of the vesicular stomatitis virus
glycoprotein (VSVG). VSVG is responsible for membrane
attachment and membrane fusion in rhabdoviruses.293 In
regard to EV engineering, VSVG can be incorporated to the
EV membrane through passive endogenous loading.294 VSVG
can then induce EV membrane fusion in a similar mechanism
as it does with viral envelopes, encouraging EV cargo
release.292 The list of molecular engineering strategies to
encourage EV cargo delivery is continuously expanding.
Current Developments. Even as EVs prove effective in
clinical trials, as an emerging next-generation drug delivery
platform there are certain areas which remain the focus of
ongoing research. For one, EV heterogeneity has been
historically addressed on the EV population level. The
heterogeneous composition of any EV population adds a
layer of complexity to their use. To further resolve this, there is
a strong focus on developing single-particle characterization
methods for EV analysis.295 By examining EVs on the single-
particle level, the numerous variables effecting EV activity can
be better described.
Additionally, there is a strong focus on elucidating in vivo
uptake pathways which drive the therapeutic outcome of EVs.
As discussed above, there exist quantitative models for
investigating EV uptake in vitro and in vivo, but there is no
current consensus regarding the mode of EV uptake in
vivo.239,296 Further, the fate of EV cargo within acceptor cells in
vivo has yet to be completely elucidated, even though the
therapeutic outcomes are quantifiably tangible.
There also exists a practical need in the lack of a standard
EV-dosing protocol. As mentioned, EVs are nanoparticles
which contain proteins, lipids, nucleic acids, and other
biomolecules as cargo. A significant problem with dosing
EVs lies in the fact that none of these molecular species
correlate perfectly with the overall EV number.297 These ratios
of the EV cargo to the particle number can be influenced by
several factors, including the method of EV isolation and the
method of EV quantitation. EVs have historically been
quantified by the total particle number, the mass of either
protein or lipid, or the presence of specific molecules such as
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RNA. While it may seem optimal to use the RNA
concentration to dose RNA-loaded EVs, the RNA quantitation
can be confounded by nonvesicular RNA which is can be
present in the final EV preparation in the form of
ribonuclearproteins.298−300
In conclusion, the potential of using EVs as an RNA
therapeutic strategy lies in their ability to combine biological
and physical engineering approaches. Each challenge that arises
in RNA delivery can be addressed individually and through a
range of techniques, as highlighted by the studies discussed
herein. As broader genetic engineering approaches develop, the
therapeutic EV field will directly benefit.
CONCLUDING REMARKS
The number of clinical and preclinical studies involving RNA
therapies, and specifically ON therapies, is rapidly expanding.
Only a small number of possible combinations of ON
chemistries, targets, and formulations have been investigated
to datea sign that the ON and RNA therapeutic fields are
still just in their early days. Nevertheless, ONs have already
successfully proven effective to target DNA, RNA, pre-mRNA,
and proteins. These qualities firmly establish ONs as a
therapeutic class. Separately, biological and synthetic nano-
carriers such as EVs and LNPs are each in their own early
stages of development but are rapidly gaining attention. As all
of these individual advancements come together, the coming
years should witness an inflection point in the rate of
development of RNA therapeutics.
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VOCABULARY
oligonucleotide, a short (15−20 bp) strand of natural or
synthetic nucleic acids; endosomal escape, the point in drug
delivery in which the active molecule breaches the endosomal
membrane to enter the cell cytosol; gapmers, structurally
unique ONs which bind to and initiate the degradation of their
target RNA in an RNase H-dependent mechanism; splice-
switching ONs, ONs which act to redirect the splicing
repertoire of the target sequence by blocking the normal
assembly of the splicing machinery to the pre-mRNA;
extracellular vesicle, a nanosized lipid-bilayer-bound particle
naturally released from cells; lipid nanoparticle, spherical
vesicles composed at least partially of ionizable lipids
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